FindTrial
Sign In

E/C/F/TDF

DRUG7 trials

Sponsors

Gilead Sciences

Conditions

Acquired Immunodeficiency SyndromeHIVHIV InfectionsHIV-1 Infection

Phase 2

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
CompletedNCT01497899
Gilead SciencesAcquired Immunodeficiency Syndrome, HIV Infections
Start: 2011-12-28End: 2016-08-22Updated: 2018-11-19

Phase 3

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
CompletedNCT01363011
Gilead SciencesAcquired Immunodeficiency Syndrome, HIV Infections
Start: 2011-05-31End: 2015-02-28Updated: 2016-05-02
Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women
CompletedNCT01705574
Gilead SciencesAcquired Immunodeficiency Syndrome, HIV Infections
Start: 2012-10-24End: 2018-09-06Updated: 2019-09-20
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
CompletedNCT01780506
Gilead SciencesHIV, HIV Infections
Start: 2012-12-26End: 2017-09-06Updated: 2018-11-19
Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
CompletedNCT01797445
Gilead SciencesHIV, HIV Infections
Start: 2013-03-12End: 2018-10-03Updated: 2020-03-02
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
CompletedNCT01815736
Gilead SciencesHIV, HIV Infections
Start: 2013-03-27End: 2020-04-01Updated: 2021-04-13
Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women
CompletedNCT02652624
Gilead SciencesHIV-1 Infection
Start: 2016-02-19End: 2018-11-26Updated: 2020-03-04

Related Papers

Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials
HIV Medicine2022-08-178 citations
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
Carolina Digital Repository (University of North Carolina at Chapel Hill)2020-04-22
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial
JAIDS Journal of Acquired Immune Deficiency Syndromes2019-10-1454 citations
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment
AIDS Research and Human Retroviruses2018-01-2588 citations
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
2017-03-0257 citations
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
2016-05-2768 citations
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
2015-11-02223 citations
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
2015-04-15429 citations